KDNY News and Press, Chinook Therapeutics Inc Com From 03/27/23

2023-03-27 08:19:05 ET Summary Omeros Corp's Q4 2022 earnings show a cash runway extending into 2025 and anticipation of Phase 3 trial readout of Narsoplimab in IgAN during 3Q23. The ARTEMIS Phase 3 trial in IgAN remains on track, and positive trial data could make Narsoplimab the...

SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced presentations at the ISN World Congress of Nephrology 2023 fro...

SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtu...

2023-03-06 14:19:25 ET Piper Sandler has initiated Chinook Therapeutics ( NASDAQ: KDNY ) with a buy rating citing the potential of atrasentan, which is in phase 3, for IgA nephropathy. The firm has a price target of $41 (~73% upside based on Friday's close). Ana...

Chinook Therapeutics ( NASDAQ: KDNY ) gained ~4% Wednesday after Guggenheim launched its coverage with a Buy recommendation, noting its place in the emerging renal market as the kidney disease drug developer advances multiple candidates against IgA nephropathy (IgAN). The company ...

SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 5 th Chronic Kidney Disease D...

Chinook Therapeutics press release ( NASDAQ: KDNY ): Q4 GAAP EPS of -$0.90 misses by $0.11 . Revenue of $0.51M beats by $0.41M . For further details see: Chinook Therapeutics GAAP EPS of -$0.90 misses by $0.11, revenue of $0.51M beats by $0.41M

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the fourth quarter and year ended December...

Summary Travere's FILSPARI (sparsentan) received accelerated approval for IgAN's disease on Feb 17, 2023. Chinook has a similar phase 3 ERA atrasentan that drove a UPCR benefit of 54.7%, and approval of sparsentan based on UPCR only should be net positive for atrasentan. We reiterat...

Summary Sparsentan is approved for IgAN with a disappointing FDA label. We believe the approval is fully priced in, and we expect disappointing sales print during the first few years and fierce competition with Chinook's Atrasentan later on. Sparsentan is expected to launch in Feb 2...